Welcome to our dedicated page for Connect Biopharma Holdings news (Ticker: CNTB), a resource for investors and traders seeking the latest updates and insights on Connect Biopharma Holdings stock.
Connect Biopharma Holdings Limited reports clinical and corporate developments for a clinical-stage biopharmaceutical company focused on inflammatory diseases. Its principal program is rademikibart, an antibody designed to target interleukin-4-receptor alpha, with company updates centered on asthma, chronic obstructive pulmonary disease and moderate-to-severe atopic dermatitis.
Recurring news includes rademikibart clinical data, Seabreeze STAT asthma and COPD study updates, Data Monitoring Committee and regulatory-related disclosures, partner activity involving Simcere in China, financial results, financing activity, investor conference participation and governance matters.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Connect Biopharma (Nasdaq: CNTB) announced that it is on track to submit a New Drug Application (NDA) for its lead drug candidate, CBP-201, for the treatment of moderate-to-severe atopic dermatitis in China by the end of Q1 2024. The submission could lead to potential approval by 2025. Encouraging results from pivotal trials in China and global data presented at the AAD Annual Meeting support the efficacy of CBP-201. Connect Biopharma has also completed enrollment for a Phase 2 global trial in asthma and reported positive topline data from the ongoing China pivotal trial for CBP-201. However, the company reported a net loss of RMB 797.1 million in 2022, a decrease from RMB 1,306.8 million in 2021, while its cash reserves declined to RMB 1,127.3 million. R&D expenses increased to RMB 652.2 million due to advancing clinical trials.